Skip to Content
November 14, 2017  •  Whitepaper

Medical Device De Novo Classification Applications: Frequently Asked Questions and What You Need to Know.

Overview In recent years, the FDA has overhauled the De Novo program to make it simpler and more attractive to medical device manufacturers. This increased emphasis has resulted in an accelerated rate of change in the Agency's regulations, processes and procedures, including the recent guidance document…

Read More
July 7, 2017  •  News

Biologics Consulting Expands Pharmacology-Toxicology Expertise; Adds Two Senior Consultants To Growing Team

Biologics Consulting, a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices, announced today the expansion of its Pharmacology-Toxicology team with the addition of two new senior consultants with more than two decades of combined experience…

Read More
April 24, 2017  •  News

Biologics Consulting Assists BriaCell Therapeutics In Gaining FDA Clearance To Initiate A Phase I/IIa Clinical Trial Of BriaVax™

Biologics Consulting, a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices, announced today that its Chemistry, Manufacturing, and Controls (CMC) Specialty Group advised BriaCell Therapeutics Corp. (TSXV: BCT) (OCTCQB: BCTXF), a clinical-stage…

Read More
January 5, 2017  •  News

IDRI Expands Board of Directors with Former FDA Leader Norman Baylor

IDRI (Infectious Disease Research Institute) is expanding its Board of Directors, comprised of international leaders in industry and academia, with the recent addition of Norman Baylor, Ph.D., who has extensive experience in the field of vaccines and vaccine-related products, including 20 years with…

Read More
January 4, 2017  •  News

Biologics Consulting Expands Footprint, Opens New Office in Maryland’s Technology Corridor

Biologics Consulting, a full-service regulatory and product development consulting firm focused on the life sciences industry, announced today that it is opening a new office in the center of Maryland's Technology Corridor and Life Sciences Hub. The new office is located in Rockville, Maryland and will…

Read More
October 24, 2016  •  Whitepaper

Data Integrity and the Pre-Approval Inspection: An Inspector’s Experience

Overview Data integrity has always played an essential role in regulatory application review and cGMP inspections – a trend that will only continue to grow in the coming years. The FDA's April 2016 draft guidance document "Data Integrity and Compliance with cGMP" is an important step by the Agency…

Read More
August 16, 2016  •  News

Biologics Consulting Continues to Expand with the Addition of Three New Team Members

Biologics Consulting, a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices, announced today the addition of three new consultants, further increasing the company's capacity to deliver comprehensive scientific, technical and strategic guidance…

Read More
April 25, 2016  •  Whitepaper

Zika Virus: The Development of Medical Countermeasures

Overview The global concern about Zika virus continues to grow as the international community braces for its continued spread. There is currently no vaccine for the virus. However, the increasing evidence of vertical transmission, teratogenic effects and potentially severe complications such as GBS has…

Read More
April 19, 2016  •  News

Biologics Consulting Expands Services, Launches Clinical Trials Planning and Oversight Group

Biologics Consulting, a full-service regulatory and product development consulting firm for biologics, pharmaceuticals and medical devices, announces the launch of its Clinical Trials Planning and Oversight Group. The group will help small and medium-sized biopharmaceutical companies in the development…

Read More
February 3, 2016  •  Webinar

Clinical and Regulatory Considerations for Orphan Drug Applications

Overview The development of Orphan Drugs - those developed specifically to treat rare medical conditions - is growing at an astounding rate. In 2014, nearly 41%1 of all new product approvals from the FDA were for the treatment of rare diseases - a trend that is expected to continue as the exclusivity…

Read More